Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
UNLABELLED INTRODUCTION, AIMS, AND METHODS: Industrial countries' societies are challenged to counter the increasing costs of health care. The preponderance of cardiovascular diseases in middle-aged people demands new strategies to reduce the extremely high rates of early deaths and increased morbidity and thus to avert considerable costs. Prevention programmes are appropriate means to combine ...
متن کاملCost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
OBJECTIVE To determine the incremental cost-effectiveness of clopidogrel plus aspirin (C + A) compared with aspirin (A) alone during the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial from a US payer perspective. BACKGROUND Although the CHARISMA trial did not find a benefit of adding clopidogrel to aspirin in its overall study ...
متن کاملCardiovascular Perspectives Cost, Effectiveness, and Cost-Effectiveness
Incremental or marginal cost-effectiveness ratios are founded on a number of assumptions that weaken their suitability as a way to balance competing economic and clinical priorities. We therefore propose a more relevant and responsible way to gauge the impact of clinical management strategies based on “consumer protection” principles— explicit disclosure of (1) the total magnitude of expected b...
متن کاملCost-Effectiveness of Antiretroviral Therapy for Prevention
Recent empirical studies and analyses have heightened interest in the use of expanded antiretroviral therapy (ART) for prevention of HIV transmission. However, ART is expensive, approximately $600 per person per year, raising issues of the cost and cost-effectiveness of ambitious ART expansion. The goal of this review is to equip the reader with the conceptual tools and substantive background n...
متن کاملInterleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
BACKGROUND Inflammation contributes to all phases of the atherothrombotic process, and patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have increased vascular risk. Yet, it remains unknown whether direct inhibition of inflammation will reduce cardiovascular event rates. DESIGN The CANTOS will evaluate whether interleukin-1β (IL-1β) inhibition...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA Cardiology
سال: 2019
ISSN: 2380-6583
DOI: 10.1001/jamacardio.2018.4566